NeurAxis (NRXS) Competitors

NeurAxis logo
$4.22 -0.28 (-6.22%)
Closing price 11/20/2026 04:00 PM Eastern
Extended Trading
$4.18 -0.04 (-0.95%)
As of 11/20/2026 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

NRXS vs. OFIX, PROF, CLPT, PDEX, and ELMD

Should you buy NeurAxis stock or one of its competitors? NeurAxis's main competitors and comparable companies include Orthofix Medical (OFIX), Profound Medical (PROF), ClearPoint Neuro (CLPT), Pro-Dex (PDEX), and Electromed (ELMD). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does NeurAxis compare to Orthofix Medical?

Orthofix Medical (NASDAQ:OFIX) and NeurAxis (NASDAQ:NRXS) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, media sentiment, dividends and risk.

Orthofix Medical has a net margin of -5.39% compared to NeurAxis' net margin of -492.76%. NeurAxis' return on equity of 0.00% beat Orthofix Medical's return on equity.

Company Net Margins Return on Equity Return on Assets
Orthofix Medical-5.39% -10.32% -5.19%
NeurAxis -492.76%N/A -641.25%

Orthofix Medical has a beta of 0.66, suggesting that its stock price is 34% less volatile than the broader market. Comparatively, NeurAxis has a beta of 1.39, suggesting that its stock price is 39% more volatile than the broader market.

89.8% of Orthofix Medical shares are owned by institutional investors. Comparatively, 11.8% of NeurAxis shares are owned by institutional investors. 2.7% of Orthofix Medical shares are owned by company insiders. Comparatively, 21.1% of NeurAxis shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

NeurAxis has lower revenue, but higher earnings than Orthofix Medical. Orthofix Medical is trading at a lower price-to-earnings ratio than NeurAxis, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Orthofix Medical$822.31M0.30-$92.19M-$1.12N/A
NeurAxis$6.53M6.88-$14.63M-$1.06N/A

Orthofix Medical currently has a consensus price target of $13.50, suggesting a potential upside of 122.41%. NeurAxis has a consensus price target of $13.00, suggesting a potential upside of 208.06%. Given NeurAxis' stronger consensus rating and higher possible upside, analysts clearly believe NeurAxis is more favorable than Orthofix Medical.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Orthofix Medical
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40
NeurAxis
0 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.50

In the previous week, NeurAxis had 5 more articles in the media than Orthofix Medical. MarketBeat recorded 6 mentions for NeurAxis and 1 mentions for Orthofix Medical. Orthofix Medical's average media sentiment score of 1.22 beat NeurAxis' score of -0.28 indicating that Orthofix Medical is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Orthofix Medical
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
NeurAxis
0 Very Positive mention(s)
2 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

NeurAxis beats Orthofix Medical on 10 of the 16 factors compared between the two stocks.

How does NeurAxis compare to Profound Medical?

NeurAxis (NASDAQ:NRXS) and Profound Medical (NASDAQ:PROF) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, media sentiment, earnings, institutional ownership, dividends, analyst recommendations, valuation and risk.

Profound Medical has a net margin of -137.51% compared to NeurAxis' net margin of -492.76%. NeurAxis' return on equity of 0.00% beat Profound Medical's return on equity.

Company Net Margins Return on Equity Return on Assets
NeurAxis-492.76% N/A -641.25%
Profound Medical -137.51%-59.57%-47.87%

NeurAxis presently has a consensus price target of $13.00, indicating a potential upside of 208.06%. Profound Medical has a consensus price target of $11.50, indicating a potential upside of 79.66%. Given NeurAxis' higher possible upside, equities analysts plainly believe NeurAxis is more favorable than Profound Medical.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NeurAxis
0 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.50
Profound Medical
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
2.67

11.8% of NeurAxis shares are owned by institutional investors. Comparatively, 47.9% of Profound Medical shares are owned by institutional investors. 21.1% of NeurAxis shares are owned by company insiders. Comparatively, 1.5% of Profound Medical shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

NeurAxis has a beta of 1.39, suggesting that its share price is 39% more volatile than the broader market. Comparatively, Profound Medical has a beta of 0.79, suggesting that its share price is 21% less volatile than the broader market.

NeurAxis has higher earnings, but lower revenue than Profound Medical. Profound Medical is trading at a lower price-to-earnings ratio than NeurAxis, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NeurAxis$6.53M6.88-$14.63M-$1.06N/A
Profound Medical$16.10M14.56-$42.57M-$0.93N/A

In the previous week, NeurAxis had 5 more articles in the media than Profound Medical. MarketBeat recorded 6 mentions for NeurAxis and 1 mentions for Profound Medical. Profound Medical's average media sentiment score of 0.67 beat NeurAxis' score of -0.28 indicating that Profound Medical is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
NeurAxis
0 Very Positive mention(s)
2 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Profound Medical
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Profound Medical beats NeurAxis on 9 of the 16 factors compared between the two stocks.

How does NeurAxis compare to ClearPoint Neuro?

NeurAxis (NASDAQ:NRXS) and ClearPoint Neuro (NASDAQ:CLPT) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, valuation, dividends and media sentiment.

ClearPoint Neuro has a net margin of -79.43% compared to NeurAxis' net margin of -492.76%. NeurAxis' return on equity of 0.00% beat ClearPoint Neuro's return on equity.

Company Net Margins Return on Equity Return on Assets
NeurAxis-492.76% N/A -641.25%
ClearPoint Neuro -79.43%-170.24%-37.00%

NeurAxis has a beta of 1.39, indicating that its share price is 39% more volatile than the broader market. Comparatively, ClearPoint Neuro has a beta of 1.38, indicating that its share price is 38% more volatile than the broader market.

NeurAxis currently has a consensus target price of $13.00, indicating a potential upside of 208.06%. ClearPoint Neuro has a consensus target price of $24.33, indicating a potential upside of 252.15%. Given ClearPoint Neuro's higher possible upside, analysts clearly believe ClearPoint Neuro is more favorable than NeurAxis.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NeurAxis
0 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.50
ClearPoint Neuro
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33

11.8% of NeurAxis shares are owned by institutional investors. Comparatively, 30.1% of ClearPoint Neuro shares are owned by institutional investors. 21.1% of NeurAxis shares are owned by company insiders. Comparatively, 6.9% of ClearPoint Neuro shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

NeurAxis has higher earnings, but lower revenue than ClearPoint Neuro. ClearPoint Neuro is trading at a lower price-to-earnings ratio than NeurAxis, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NeurAxis$6.53M6.88-$14.63M-$1.06N/A
ClearPoint Neuro$36.97M5.99-$25.54M-$1.21N/A

In the previous week, NeurAxis had 6 more articles in the media than ClearPoint Neuro. MarketBeat recorded 6 mentions for NeurAxis and 0 mentions for ClearPoint Neuro. ClearPoint Neuro's average media sentiment score of 0.00 beat NeurAxis' score of -0.28 indicating that ClearPoint Neuro is being referred to more favorably in the news media.

Company Overall Sentiment
NeurAxis Neutral
ClearPoint Neuro Neutral

Summary

NeurAxis beats ClearPoint Neuro on 9 of the 16 factors compared between the two stocks.

How does NeurAxis compare to Pro-Dex?

Pro-Dex (NASDAQ:PDEX) and NeurAxis (NASDAQ:NRXS) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, media sentiment, risk, valuation and institutional ownership.

Pro-Dex has higher revenue and earnings than NeurAxis. NeurAxis is trading at a lower price-to-earnings ratio than Pro-Dex, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pro-Dex$77.55M2.60$13.66M$3.6517.26
NeurAxis$6.53M6.88-$14.63M-$1.06N/A

In the previous week, Pro-Dex had 10 more articles in the media than NeurAxis. MarketBeat recorded 16 mentions for Pro-Dex and 6 mentions for NeurAxis. Pro-Dex's average media sentiment score of 1.08 beat NeurAxis' score of -0.28 indicating that Pro-Dex is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Pro-Dex
3 Very Positive mention(s)
2 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
NeurAxis
0 Very Positive mention(s)
2 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

15.3% of Pro-Dex shares are owned by institutional investors. Comparatively, 11.8% of NeurAxis shares are owned by institutional investors. 48.0% of Pro-Dex shares are owned by insiders. Comparatively, 21.1% of NeurAxis shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Pro-Dex has a net margin of 15.12% compared to NeurAxis' net margin of -492.76%. Pro-Dex's return on equity of 26.18% beat NeurAxis' return on equity.

Company Net Margins Return on Equity Return on Assets
Pro-Dex15.12% 26.18% 16.69%
NeurAxis -492.76%N/A -641.25%

Pro-Dex currently has a consensus target price of $80.00, indicating a potential upside of 26.98%. NeurAxis has a consensus target price of $13.00, indicating a potential upside of 208.06%. Given NeurAxis' higher probable upside, analysts clearly believe NeurAxis is more favorable than Pro-Dex.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Pro-Dex
0 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.67
NeurAxis
0 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.50

Pro-Dex has a beta of 0.12, indicating that its stock price is 88% less volatile than the broader market. Comparatively, NeurAxis has a beta of 1.39, indicating that its stock price is 39% more volatile than the broader market.

Summary

Pro-Dex beats NeurAxis on 13 of the 16 factors compared between the two stocks.

How does NeurAxis compare to Electromed?

Electromed (NYSE:ELMD) and NeurAxis (NASDAQ:NRXS) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, earnings, media sentiment, profitability, institutional ownership and dividends.

40.8% of Electromed shares are held by institutional investors. Comparatively, 11.8% of NeurAxis shares are held by institutional investors. 11.0% of Electromed shares are held by company insiders. Comparatively, 21.1% of NeurAxis shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Electromed has a net margin of 11.34% compared to NeurAxis' net margin of -492.76%. Electromed's return on equity of 15.71% beat NeurAxis' return on equity.

Company Net Margins Return on Equity Return on Assets
Electromed11.34% 15.71% 13.37%
NeurAxis -492.76%N/A -641.25%

Electromed has higher revenue and earnings than NeurAxis. NeurAxis is trading at a lower price-to-earnings ratio than Electromed, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Electromed$75.57M2.49$5.15M$1.3816.65
NeurAxis$6.53M6.88-$14.63M-$1.06N/A

Electromed has a beta of 0.43, indicating that its stock price is 57% less volatile than the broader market. Comparatively, NeurAxis has a beta of 1.39, indicating that its stock price is 39% more volatile than the broader market.

In the previous week, NeurAxis had 5 more articles in the media than Electromed. MarketBeat recorded 6 mentions for NeurAxis and 1 mentions for Electromed. Electromed's average media sentiment score of 0.76 beat NeurAxis' score of -0.28 indicating that Electromed is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Electromed
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
NeurAxis
0 Very Positive mention(s)
2 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Electromed currently has a consensus price target of $43.75, indicating a potential upside of 90.38%. NeurAxis has a consensus price target of $13.00, indicating a potential upside of 208.06%. Given NeurAxis' higher possible upside, analysts plainly believe NeurAxis is more favorable than Electromed.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Electromed
0 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.75
NeurAxis
0 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.50

Summary

Electromed beats NeurAxis on 11 of the 16 factors compared between the two stocks.

Get NeurAxis News Delivered to You Automatically

Sign up to receive the latest news and ratings for NRXS and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NRXS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NRXS vs. The Competition

MetricNeurAxisHealthcare Equipment & Supplies IndustryHealthcare SectorNASDAQ Exchange
Market Cap$44.96M$5.95B$7.78B$11.72B
Dividend YieldN/A1.69%2.47%4.72%
P/E Ratio-2.2937.4533.4528.24
Price / Sales6.885.158.105.42
Price / CashN/A23.6221.0121.90
Price / Book-15.634.024.263.50
Net Income-$14.63M$142.56M$3.50B$394.12M
1 Month Performance-46.72%-8.33%-10.48%-12.15%
1 Year Performance61.07%-4.46%-4.61%-11.41%

NeurAxis Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NRXS
NeurAxis
2.3088 of 5 stars
$4.22
-6.2%
$13.00
+208.1%
+68.1%$44.96M$6.53MN/A24
OFIX
Orthofix Medical
3.8926 of 5 stars
$7.18
+0.8%
$14.75
+105.4%
-57.5%$290.02M$835.41MN/A1,605
PROF
Profound Medical
2.0851 of 5 stars
$7.85
+2.2%
$11.50
+46.5%
+8.9%$281.30M$23.63MN/A162
CLPT
ClearPoint Neuro
1.9226 of 5 stars
$9.17
+4.6%
$24.33
+165.4%
-48.9%$281.11M$45.49MN/A172
PDEX
Pro-Dex
3.5661 of 5 stars
$71.49
+2.3%
$74.00
+3.5%
+104.3%$223.55M$77.55M19.14206

Related Companies and Tools


This page (NASDAQ:NRXS) was last updated on 11/21/2026 by MarketBeat.com Staff.
From Our Partners